Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CLPP | Q16740 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256675 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AATMGAA | |
| SCHEMBL5731330 | 0.85 | MEN1 (0.44) | ALDH1A1MEN1KMT2AATMHRH4 | |
| SCHEMBL3297432 | 0.82 | MEN1 (0.43) | ALDH1A1MEN1KMT2AATMGAA | |
| SCHEMBL3251169 | 0.82 | MEN1 (0.43) | ALDH1A1MEN1KMT2AATMGAA | |
| SCHEMBL3251081 | 0.82 | KDM1A (0.45) | ALDH1A1MEN1KMT2AATMGAA | |
| SCHEMBL3255040 | 0.81 | KDM1A (0.49) | ALDH1A1MEN1KMT2AATMSIGMAR1 | |
| SCHEMBL3256934 | 0.81 | KDM1A (0.49) | ALDH1A1MEN1KMT2AATMSIGMAR1 | |
| SCHEMBL3248354 | 0.79 | KDM1A (0.45) | MEN1KMT2AATMKDM1A | |
| SCHEMBL3255880 | 0.79 | KDM1A (0.45) | MEN1KMT2AATMKDM1A | |
| SCHEMBL3254185 | 0.79 | KDM1A (0.48) | ALDH1A1MEN1KMT2AATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | ALDH1A1 1913/4885MEN1 3313/4885KMT2A 3229/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | ALDH1A1 1913/4885MEN1 3313/4885KMT2A 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.